Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 8/20 | 0.56 |
| ▸ | TK1 | P04183 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TYMP | P19971 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL591657 | 0.98 | TK1 (0.56) | TK2TK1HPGDMAPTCYP2C9 | |
| SCHEMBL2496425 | 0.93 | HPGD (0.55) | TK2TK1HPGDMAPTCYP2C9 | |
| SCHEMBL7124047 | 0.93 | HPGD (0.55) | TK2TK1HPGDMAPTCYP2C9 | |
| SCHEMBL15110503 | 0.86 | TK2 (0.60) | TK2TK1HPGDMAPTCYP2C9 | |
| SCHEMBL18226895 | 0.85 | TK1 (0.65) | TK2TK1HPGDMAPTCYP2C9 | |
| SCHEMBL6890252 | 0.85 | TK1 (0.65) | TK2TK1HPGDMAPTCYP2C9 | |
| SCHEMBL10337895 | 0.85 | TK1 (0.65) | TK2TK1HPGDMAPTCYP2C9 | |
| SCHEMBL6883307 | 0.85 | TK1 (0.65) | TK2TK1HPGDMAPTCYP2C9 | |
| SCHEMBL3465151 | 0.84 | TK2 (0.56) | TK2TK1HPGDMAPTCYP2C9 | |
| SCHEMBL26034750 | 0.84 | TK2 (0.56) | TK2TK1HPGDMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030322-B2 | Spirocompounds useful as modulators for dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2011-10-04 | — | — | US | disclosed |
| US-8030322-B2 | Spirocompounds useful as modulators for dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2011-10-04 | — | — | US | disclosed |
| US-8030322-B2 | Spirocompounds useful as modulators for dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2011-10-04 | — | — | US | disclosed |
| US-7727988-B2 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2010-06-01 | — | — | US | disclosed |
| US-7727988-B2 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2010-06-01 | — | — | US | disclosed |
| US-20100063078-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063078-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063078-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063078-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | NR3C2, DRD3, TACR1 | TK2 4325/4885TK1 2812/4885HPGD 1651/4885 |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | AZI2, NT5C3B, CYP1B1 | TK2 723/4885TK1 386/4885HPGD 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.